secwatch.observer — SEC 8-K summary
======================================

Issuer:     BNB PLUS CORP. (BNBX)
CIK:        0000744452
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001104659-23-089781
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Applied DNA Q3 revenue down to $2.9M; net loss widens to $3.1M; acquires Spindle Biotech
--------------------------------------------------------------------------------

- Revenue $2.9M vs $4.3M YoY; decline driven by COVID-19 testing drop and CUNY contract wind-down.
- Net loss $3.1M vs $1.1M YoY; operating loss flat at $2.9M; gross margin improved to 44%.
- Cash $10.8M at June 30, down from $12.3M at March 31; Adjusted EBITDA -$2.1M.
- Acquired Spindle Biotech post-quarter; launched Linea IVT platform for mRNA production.
- NYSDOH PGx diagnostic approval pending; added new CertainT customers for supply chain traceability.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744452/000110465923089781/0001104659-23-089781-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744452/000110465923089781/tm2323420d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-089781

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer